Yeztugo Lenacapavir Is Now the First and Only FDA Approved HIV . . . Individuals must be tested for HIV-1 infection prior to initiating Yeztugo, and with each subsequent injection of Yeztugo, using a test approved or cleared by the FDA for the diagnosis of acute or primary HIV-1 infection Drug-resistant HIV-1 variants have been identified with use of Yeztugo by individuals with undiagnosed HIV-1 infection
FDA approves twice-a-year injection for HIV prevention - CNN A drug currently used to treat certain HIV infections has also, on Wednesday, received approval from the US Food and Drug Administration to be used to prevent HIV Gilead Sciences, maker of the
FDA Approves First Twice-a-Year HIV Prevention Shot, Yeztugo On Wednesday, the U S Food and Drug Administration (FDA) approved lenacapavir, a long-acting injection that was shown to be nearly 100% effective in clinical trials Lenacapavir is the second long-acting drug approved to prevent HIV The first, Apretude, is given every two months and is used by about 21,000 Americans By comparison, nearly
Gilead Wins Historic Approval for Twice-Yearly HIV Drug The FDA approved Gilead’s landmark long-acting HIV treatment lenacapavir Wednesday afternoon The drug will be marketed under the name Yeztugo Lenacapavir had already been approved in 2022 and sold under a different name, Sunlenca That approval only applied to patients with treatment-resistant HIV and who had received prior treatment
For HIV AIDS, FDA approves next best thing to a vaccine | STAT HIV protection with just two shots a year: FDA approves Gilead drug Lenacapavir, to be sold as Yeztugo, has potential to bring AIDS pandemic to heel but faces Trump-era obstacles Manage alerts for
The FDA Just Approved a Long-Lasting Injection to Prevent HIV The US Food and Drug Administration has just approved lenacapavir, an injectable form of HIV prevention that is almost 100 percent effective and requires only two doses per year Science magazine
FDA approves twice-yearly shot of Gilead drug for HIV prevention The Food and Drug Administration has approved a new way to prevent HIV, clearing a Gilead Sciences drug that requires only two injections a year to protect against infections The treatment, known scientifically as lenacapavir and to be sold as Yeztugo, was approved on Wednesday to reduce the risk of sexually acquired HIV infections in adults and adolescents who weigh at least 35 kilograms